stockrowLigand Pharmaceuticals Incorporated
LGND Healthcare Biotechnology
Ligand Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $268.1 million, up 60.4% from fiscal 2024.
- Revenue
- −31.8%
- EPS
- −123.9%
- Free cash flow
- −268.5%
- Total debt
- +52.6%
Quarter to September 2026, against a year earlier
Follow LGND
Alert me
Ligand Pharmaceuticals Incorporated (LGND) Return on equity
Ligand Pharmaceuticals Incorporated's return on equity over the twelve months to 30 September 2026 was 5.38%, down 8.1 percentage points from fiscal 2025 (13.5%). Over the past ten years it has ranged from −4.70% (fiscal 2022) to 175.7% (fiscal 2015); the current reading is higher than 73% of that period. That is above the Biotechnology industry median of −50.1% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 13.5% | 14.00 |
| FY2024 | −0.53% | (8.56) |
| FY2023 | 8.03% | 12.73 |
| FY2022 | −4.70% | (12.17) |
| FY2021 | 7.47% | 7.87 |
| FY2020 | −0.40% | (95.16) |
| FY2019 | 94.8% | 64.92 |
| FY2018 | 29.8% | 26.45 |
| FY2017 | 3.39% | 3.96 |
| FY2016 | −0.57% | (176.22) |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| PTCT PTC Therapeutics, Inc. compare | 61.1% |
| LGND Ligand Pharmaceuticals Incorporated | 5.38% |
| BLTE Belite Bio, Inc. Sponsored ADR compare | 0.00% |
| ORKA Oruka Therapeutics, Inc. compare | −18.3% |
| CGON CG Oncology, Inc. compare | −26.4% |
| IMVT Immunovant, Inc. compare | −80.1% |
| IONS Ionis Pharmaceuticals, Inc. compare | −105.5% |
| KOD Kodiak Sciences Inc. compare | −368.4% |
| MIRM Mirum Pharmaceuticals, Inc. compare | −760.0% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on LGND
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement